Showing 1401-1410 of 3024 results for "".
- Phosphorylated α-Synuclein Detectable by Skin Biopsy in Those with Synucleionopathies Including Parkinson Diseasehttps://practicalneurology.com/news/phosphorylated-a-synuclein-detectable-by-skin-biopsy-in-those-with-synucleionopathies-including-parkinson-disease/2470436/According to study results published in JAMA, a high proportion of people with Parkinson disease (PD), multiple system atrophy (MSA), dementia with Lewy bodies (DLB), and pure autonomic failure (PAF) showed skin biopsies positive for cutaneous phosphorylated α-synuclein. The result
- Ampreloxetine May Be Effective at Treating Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophyhttps://practicalneurology.com/news/ampreloxetine-may-be-effective-at-treating-neurogenic-orthostatic-hypotension-in-patients-with-multiple-system-atrophy/2470280/Ampreloxetine (Theravance Biopharma, South San Francisco, CA) may be a safe and effective treatment for symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA) according to study results presented at the 2023 International Congress of Parkinson’s
- FDA Issues Refusal To File Letter for New Biologics License Application for Stem Cell ALS Treatmenthttps://practicalneurology.com/news/fda-does-not-file-new-biologics-license-application-for-stem-cell-amyotrophic-lateral-sclerosis-treatment/2470068/The Food and Drug Administration (FDA) has issued a refusal to file letter for the Biologics License Application (BLA) for autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF)(NurOwn; BrainStorm Cell Therapeutics, New York, NY) as treatment of amyotrophic lateral sclerosis (A
- Study Shows Mobile Stroke Units Lead to Better Outcomeshttps://practicalneurology.com/news/study-shows-mobile-stroke-units-lead-to-better-outcomes/2469684/A study published in The New England Journal of Medicine found that people with acute ischemic stroke had better outcomes when treated in a mobile stroke unit (MSU) instead of a standard emergency medical services (EM
- Mixed Sodium Oxybates Improve Idiopathic Hypersomniahttps://practicalneurology.com/news/mixed-sodium-oxybates-improve-idiopathic-hypersomnia/2469574/In a phase 3 study (NCT03533114) of mixed salt oxybates (MSO) (Xywav; Jazz Pharmaceuticals, Philadelphia, PA) for treatment of idiopathic hypersomnia (IH) showed improvement on multiple measures. All participants first received tr
- Stem-Cell Treatment Improves Multiple Sclerosis Disability in Phase 2 Trialhttps://practicalneurology.com/news/phase-2-study-evaluating-msc-ntf-as-a-treatment-for-progressive-ms/2469545/In a phase 2 trial (NCT03799718), 3 repeated administrations of autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF) (NurOwn; BrainStorm Cell Therapeutics, New York, NY) treat
- Outcomes of Ischemic Stroke Care in Mobile Stroke Units Superior to Ambulanceshttps://practicalneurology.com/news/outcomes-of-ischemic-stroke-care-in-mobile-stroke-units-superior-to-ambulances/2469533/Data from the BEST-MSU study (NCT02190500) presented at the International Stroke Conference, held online March 17-19, 2021, showed care for individuals with ischemic stroke in mobile stroke units (MSUs) was superior compared with stand
- Nanocatalytic Gold Treatment Improves Multiple Sclerosis Functional Composite Scores in Phase 2 Studieshttps://practicalneurology.com/news/nanocatalytic-gold-treatment-improves-multiple-sclerosis-functional-composite-scoresin-phase-2-studies/2469513/Treatment with the bioenergetic catalyst nanocrystalline gold (CNM-Au8; Clene Nanomedicine, Salt Lake City, UT) improved Multiple Sclerosis Functional Composite (MSFC) scores significantly more than placebo. Participants in the trial continued taking disease-modifying treatments approved for the
- FDA Advises More Clinical Data is Need for Potential ALS Stem Cell Treatmenthttps://practicalneurology.com/news/fda-advises-more-clinical-data-for-als-clinical-development-program/2469506/The Food and Drug Administration (FDA) gave feedback about autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF)(NurOwn; BrainStorm Cell Therapeutics, New York, NY), in a phase 3 clinical trial (
- Stem Cell Treatment Responses Fails to Reach Statistical Significance and Has High Placebo Response Ratehttps://practicalneurology.com/news/stem-cell-treatment-responses-fails-to-reach-statistical-significance-and-has-high-placebo-response-rate/2469434/In a phase 3 clinical trial (NCT03280056) of autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF)(NurOwn; BrainStorm Cell Therapeutics, New York, NY), 34.7% of participants wi